{
  "success": true,
  "pagesUsed": [
    16,
    17,
    18,
    25,
    26,
    27
  ],
  "modelUsed": "claude-opus-4-5",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Safety Objective",
        "text": "To evaluate the safety and tolerability of ontamalimab 75 mg in participants with nonalcoholic steatohepatitis (NASH) and liver fibrosis",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1",
          "ep_2",
          "ep_3",
          "ep_4",
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Biomarker Objective",
        "text": "To evaluate the effect of ontamalimab on biomarkers and noninvasive tests in participants with NASH and liver fibrosis",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6",
          "ep_7",
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Exploratory Biomarker Objective",
        "text": "To explore additional biomarkers and noninvasive test assessments",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Pharmacokinetic Objective",
        "text": "To characterize the pharmacokinetics of ontamalimab in participants with NASH and liver fibrosis",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Treatment-Emergent Adverse Events",
        "text": "Incidence and severity of treatment-emergent adverse events (TEAEs)",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_2",
        "name": "Serious Adverse Events",
        "text": "Incidence of serious adverse events (SAEs)",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_3",
        "name": "Clinical Laboratory Tests",
        "text": "Clinical laboratory test results summarized by visit including potentially clinically significant findings",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_4",
        "name": "Vital Signs",
        "text": "Vital signs and body weight summarized by visit",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_5",
        "name": "ECG Findings",
        "text": "Electrocardiogram (ECG) findings summarized by visit",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_6",
        "name": "Pro-C3 Change from Baseline",
        "text": "Percent change from baseline in Pro-C3 at Week 24 analyzed using a mixed effects model for repeated measure (MMRM)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_7",
        "name": "ELF Change from Baseline",
        "text": "Percent change from baseline in Enhanced Liver Fibrosis (ELF) score at Week 24 analyzed using a mixed effects model for repeated measure (MMRM)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_8",
        "name": "cT1 MRI Change from Baseline",
        "text": "Change from baseline in iron-corrected T1 (cT1) MRI at Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_9",
        "name": "Exploratory Biomarkers and Noninvasive Tests",
        "text": "Additional biomarkers and noninvasive test assessments including liver stiffness measurement, liver fat content, FibroScan-AST score, Agile 4 score, Fibrosis-4 Index, Child-Pugh score, Model for End-stage Liver Disease, and HepQuant-SHUNT Disease Severity Index",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_10",
        "name": "Pharmacokinetic Concentrations",
        "text": "Pharmacokinetic concentration values of ontamalimab",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      }
    ],
    "estimands": [],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 2,
      "exploratoryObjectives": 1,
      "totalEndpoints": 10,
      "totalEstimands": 0
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Safety Objective",
        "text": "To evaluate the safety and tolerability of ontamalimab 75 mg in participants with nonalcoholic steatohepatitis (NASH) and liver fibrosis",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Primary Objective"
        },
        "endpointIds": [
          "ep_1",
          "ep_2",
          "ep_3",
          "ep_4",
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Biomarker Objective",
        "text": "To evaluate the effect of ontamalimab on biomarkers and noninvasive tests in participants with NASH and liver fibrosis",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_6",
          "ep_7",
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Exploratory Biomarker Objective",
        "text": "To explore additional biomarkers and noninvasive test assessments",
        "level": {
          "code": "Exploratory",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Exploratory Objective"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Pharmacokinetic Objective",
        "text": "To characterize the pharmacokinetics of ontamalimab in participants with NASH and liver fibrosis",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Treatment-Emergent Adverse Events",
        "text": "Incidence and severity of treatment-emergent adverse events (TEAEs)",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_2",
        "name": "Serious Adverse Events",
        "text": "Incidence of serious adverse events (SAEs)",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_3",
        "name": "Clinical Laboratory Tests",
        "text": "Clinical laboratory test results summarized by visit including potentially clinically significant findings",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_4",
        "name": "Vital Signs",
        "text": "Vital signs and body weight summarized by visit",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_5",
        "name": "ECG Findings",
        "text": "Electrocardiogram (ECG) findings summarized by visit",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_6",
        "name": "Pro-C3 Change from Baseline",
        "text": "Percent change from baseline in Pro-C3 at Week 24 analyzed using a mixed effects model for repeated measure (MMRM)",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Biomarker",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_7",
        "name": "ELF Change from Baseline",
        "text": "Percent change from baseline in Enhanced Liver Fibrosis (ELF) score at Week 24 analyzed using a mixed effects model for repeated measure (MMRM)",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Biomarker",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_8",
        "name": "cT1 MRI Change from Baseline",
        "text": "Change from baseline in iron-corrected T1 (cT1) MRI at Week 24",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Biomarker",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_9",
        "name": "Exploratory Biomarkers and Noninvasive Tests",
        "text": "Additional biomarkers and noninvasive test assessments including liver stiffness measurement, liver fat content, FibroScan-AST score, Agile 4 score, Fibrosis-4 Index, Child-Pugh score, Model for End-stage Liver Disease, and HepQuant-SHUNT Disease Severity Index",
        "level": {
          "code": "Exploratory",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Exploratory Endpoint"
        },
        "purpose": "Biomarker",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_10",
        "name": "Pharmacokinetic Concentrations",
        "text": "Pharmacokinetic concentration values of ontamalimab",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Pharmacokinetic",
        "instanceType": "Endpoint"
      }
    ],
    "estimands": []
  }
}